About immucell - ICCC
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. It operates through the following segments: Scours and Mastitis. The Scours segment consists of the First Defense product line. The Mastitis segment includes the CMT product line consisting of reagents and equipment used for rapid cow-side testing to identify mastitic quarters by detecting elevated somatic cell counts. The company was founded in 1982 and is headquartered in Portland, ME.
ICCC At a Glance
ImmuCell Corp.
56 Evergreen Drive
Portland, Maine 04103
| Phone | 1-207-878-2770 | Revenue | 27.64M | |
| Industry | Biotechnology | Net Income | -1,040,027.00 | |
| Sector | Health Technology | 2025 Sales Growth | 4.345% | |
| Fiscal Year-end | 12 / 2026 | Employees | 73 | |
| View SEC Filings |
ICCC Valuation
| P/E Current | 117.998 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.008 |
| Price to Book Ratio | 2.056 |
| Price to Cash Flow Ratio | 22.43 |
| Enterprise Value to EBITDA | 14.821 |
| Enterprise Value to Sales | 2.348 |
| Total Debt to Enterprise Value | 0.203 |
ICCC Efficiency
| Revenue/Employee | 378,687.315 |
| Income Per Employee | -14,246.945 |
| Receivables Turnover | 8.012 |
| Total Asset Turnover | 0.631 |
ICCC Liquidity
| Current Ratio | 4.259 |
| Quick Ratio | 1.93 |
| Cash Ratio | 0.957 |
ICCC Profitability
| Gross Margin | 41.402 |
| Operating Margin | 5.966 |
| Pretax Margin | -3.72 |
| Net Margin | -3.762 |
| Return on Assets | -2.374 |
| Return on Equity | -3.811 |
| Return on Total Capital | -2.584 |
| Return on Invested Capital | -2.625 |
ICCC Capital Structure
| Total Debt to Total Equity | 48.768 |
| Total Debt to Total Capital | 32.781 |
| Total Debt to Total Assets | 31.022 |
| Long-Term Debt to Equity | 42.50 |
| Long-Term Debt to Total Capital | 28.568 |